1. Recap of Day One Peter Chibatamoto

2. Opening Session Objectives of the workshop Opening remarks by NC – Cited a number of papers emphasizing the rationale for implementing TRIPS – HLM 2011 political declaration and other UN documents (MDGs) – Local strategic documents such as Vision 2016, NDP 10NSF II – Sustainability issue is critical

3. PRESENTATIONS Mandates of SARPAM and UNDP Access to Medicines – Policy and Issues in Botswana Procurement of patented and other essential medicines Overview of Patents, TRIPS, Flexibilities and Access to medicines Botswana IP situation

4. Discussions What happens to CMS when patency of drugs expires Examine the reduction of costs Resistance of drugs Patency search is done at a fee Botswana market is small for big companies – not a priority for companies and hence Botswana has to run around looking for those willing Local production – will create employment (economic diversification) Need for feasibility study on options – especially local productions Need to plan for future – to curb resistance

5. Plenary Group I (Health) Patented medicines are expensive Limited access to generic drugs Lack of local production Limited efforts in coordinating TRIPS implementation Lack of information between pvt and public sector Week logistic management information and week supply chain management

6. Group II (Civil Society) Meaningful involvement and participation Capacity to comprehend the concept of TRIPS – awareness Civil society is dealing with communities and hence the need to be assisted with packaging information

7. Group III {Legal and Trade} Conflict between completion Act and Industrial Property Act Counterfeit laws Patentability criteria is not clear It does not prevent ever greening SACU-EFTA- FTA agreement – harmonization of laws with European community =need to reflect during the 2014 negotiations

8. Discussion Issue of retaliation (human rights issue – how real is it?). It has happened in Thailand. Its possible Bench marking with Europe – it has to do with easy market access. Negotiation in bad faith

9. THANK YOU